Since 2002, imatinib mesylate (IM), a tyrosine kinase inhibitor that targets KIT and PDGFRA in GIST, has emerged as the gold standard therapy for metastatic and unresectable GIST. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.